Patents by Inventor Kashi Javaherian

Kashi Javaherian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210363225
    Abstract: The present invention pertains to a method for producing a protein oligomer comprising at least two, and preferably three heterodimeric human NC-I-Fc proteins, the method comprising: a) culturing a host cell expressing (i) a fusion protein comprising, from N- to C-terminus, human NC-1 from collagen 18 fused to human IgGI Fc with “knob” mutations, or human IgGI Fc with “knob” mutations fused to human NC-1 from collagen 18, and (ii) human IgGI Fc with “hole” mutations, under conditions which allow the formation of a protein oligomer comprising at least two, and preferably three heterodimeric human NC-1-Fc proteins, and wherein the fusion protein of (i) and the human IgGI Fc with “hole” mutations of (ii) are expressed in a ratio of 2:1 or higher, and b) obtaining the protein oligomer comprising at least two, and preferably three heterodimeric human NC-1-Fc proteins.
    Type: Application
    Filed: April 16, 2019
    Publication date: November 25, 2021
    Inventors: Kashi Javaherian, Jürgen Debus, Amir Abdollahi
  • Publication number: 20200270332
    Abstract: The present invention is concerned with a protein oligomer comprising (i) at least two NC-monomers of collagen 18 or (ii) at least two endostatin domains of collagen 18 or (iii) at least two N-terminal peptides of the collagen 18 endostatin domain, for use in treating, ameliorating or preventing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease. The invention further relates to the mentioned protein oligomer for use for detecting and/or diagnosing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.
    Type: Application
    Filed: December 5, 2016
    Publication date: August 27, 2020
    Inventors: Amir Abdollahi, Kashi Javaherian, Jürgen Debus, Cheng Zhou
  • Publication number: 20140302026
    Abstract: The present invention is concerned with a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a NC-1 monomer of human collagen 18 and a Fc domain of an immunoglobulin. The invention also relates to a fusion protein comprising: a) an endostatin peptide or endostatin-derived peptide and b) the RGD motif and/or PHSRN motif of Fibronectin. The invention further relates to a kit comprising the protein oligomer or fusion proteins of the invention.
    Type: Application
    Filed: August 23, 2012
    Publication date: October 9, 2014
    Applicant: Deutsches Krebsforschungszentrum
    Inventors: Tong-Young Lee, Amir Abdollahi, Kashi Javaherian
  • Patent number: 7645735
    Abstract: Provided herein are peptides from the N-terminal of endostatin proteins, including the first histidine of the protein, nucleic acids encoding the peptides, pharmaceutical compositions comprising the nucleic acids and proteins and methods for using the pharmaceutical compositions to treat or prevent endometriosis in a subject.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: January 12, 2010
    Assignee: Children's Medical Center Corporation
    Inventors: Judah Folkman, Kashi Javaherian, Christian Becker, Robert D'Amato
  • Publication number: 20090280190
    Abstract: Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.
    Type: Application
    Filed: March 6, 2009
    Publication date: November 12, 2009
    Inventors: Judah Folkman, Kashi Javaherian, Robert Tjin Tham Sjin
  • Patent number: 7524811
    Abstract: Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: April 28, 2009
    Assignee: Children's Medical Center Corporation
    Inventors: Judah Folkman, Kashi Javaherian, Robert Tjin Tham Sjin
  • Publication number: 20060258583
    Abstract: Provided herein are peptides and nucleic acids encoding the peptides, pharmaceutical compositions comprising the nucleic acids and proteins and methods for using the pharmaceuticals to treat or prevent endometriosis in a subject.
    Type: Application
    Filed: February 28, 2006
    Publication date: November 16, 2006
    Applicant: Children's Medical Center Corporation
    Inventors: Judah Folkman, Kashi Javaherian, Christian Becker, Robert D'Amato
  • Publication number: 20060251699
    Abstract: Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.
    Type: Application
    Filed: February 28, 2006
    Publication date: November 9, 2006
    Applicant: Children's Medical Center Corporation
    Inventors: Judah Folkman, Kashi Javaherian, Robert Sjin
  • Publication number: 20050196402
    Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.
    Type: Application
    Filed: November 8, 2004
    Publication date: September 8, 2005
    Applicant: REPLIGEN CORPORATION
    Inventors: Gary Gray, Jerry Carson, Kashi Javaherian, Paul Rennert, Sandra Silver
  • Publication number: 20040151725
    Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.
    Type: Application
    Filed: March 2, 2004
    Publication date: August 5, 2004
    Inventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Cindy L. Jellis, Paul D. Rennert, Sandra Silver
  • Patent number: 6750334
    Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.
    Type: Grant
    Filed: February 2, 1996
    Date of Patent: June 15, 2004
    Assignee: Repligen Corporation
    Inventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Cindy L. Jellis, Paul D. Rennert, Sandra Silver
  • Patent number: 6444792
    Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: September 3, 2002
    Assignee: Repligen Corporation
    Inventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert, Sandra Silver
  • Publication number: 20020114814
    Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.
    Type: Application
    Filed: December 20, 2001
    Publication date: August 22, 2002
    Inventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert, Sandra Silver